Israel-based digital startup RespirAI Medical has teamed up with Mayo Clinic to develop a wearable AI-based home monitoring platform for respiratory diseases.

The collaboration aims to create an inclusive platform that proactively monitors the rehabilitation of Chronic obstructive pulmonary disease (COPD) patients, after their Zephyr Valve procedure.

RespirAI said that its advanced platform will feature unique biomarkers to help patient accurately monitor their disease in real-time, from their homes.

It facilitates the early detection of disease exacerbations, which may potentially enhance disease management and medication adherence.

The platform is also expected to reduce the need for in-person visits and help save the lives of patients while reducing their healthcare costs.

RespirAI co-founder and CEO Nimrod Bin-Nun said: “Our collaboration with Mayo Clinic represents a significant likelihood and step forward in improving the lives of patients suffering from chronic conditions.

“It is an exceptional opportunity to combine new technology with established medical expertise. We firmly believe that by working together, we can reshape the patient experience and outcomes, providing better, more efficient care.”

The collaboration is centred around the Zephyr Valve procedure, a minimally invasive treatment option for individuals with COPD.

At-home patient monitoring, including tracking of physical activity and early detection of potential complications, will play a key role in mitigating risks and ensuring procedure success, said RespirAI.

The collaboration is designed to create a platform that closely monitors the rehabilitation process of patients following the Zephyr Valve procedure and identifies early signs of exacerbations.

It will improve patient monitoring and support during the critical rehabilitation period after the procedure, to enhance patient outcomes and both patients and healthcare providers.

RespirAI Medical is engaged in developing a wearable AI-based home monitoring platform to improve the management of respiratory diseases.

Its biomarker-based technology will help patients monitor their conditions in real-time, to better manage the disease and early detect the exacerbations.

Mayo Clinic has a financial interest in the technology and will use any proceeds to support its not-for-profit mission in patient care, education and research.